Harvard Bioscience(US:HBIO)2026-03-13 12:20Revenue and Sales Performance - For the year ended December 31, 2025, revenues from the Cellular and Molecular Technology (CMT) product family accounted for approximately 46% of global revenues, while the Preclinical product family represented about 54%[23][24]. - Direct sales to end-users represented approximately 61% of total revenues for the year ended December 31, 2025, while distributor sales accounted for about 39%[30]. - Sales of third-party products accounted for approximately 13% of revenues for the year ended December 31, 2025[25]. - Revenues decreased by $7.5 million, or 8.1%, to $86.6 million for the year ended December 31, 2025, compared to $94.1 million for the year ended December 31, 2024[128]. - The company reported revenues of $86,550,000 for the year ended December 31, 2025, a decrease of 8.4% compared to $94,135,000 in 2024[204]. Cost Management and Savings - The company anticipates approximately $3 million in cost savings from Project Viking in 2027, with annual savings expected to reach $4 million starting in 2028[15]. - The Company expects to achieve approximately $3 million in cost savings in 2027 and approximately $4 million in annual cost savings beginning in 2028 from Project Viking[123]. - The company is focused on maintaining operational efficiency and cost discipline while pursuing growth through research and development and potential acquisitions[21][32]. Research and Development - Research and development expenses were approximately $8.8 million for the year ended December 31, 2025, down from $10.4 million in 2024[32]. - The company has incurred and will continue to incur substantial expenses for the development of new products and enhancements to existing products, which may affect profitability if development costs are not recovered[52]. Financial Position and Performance - The company incurred a net loss of $56,700,000 in 2025, significantly higher than the net loss of $12,405,000 in 2024, resulting in a loss per share of $1.28 compared to $0.28 in the previous year[204]. - Cash and cash equivalents increased to $8.6 million as of December 31, 2025, compared to $4.1 million as of December 31, 2024[142]. - Total current assets increased to $48,225,000 in 2025 from $45,117,000 in 2024, primarily driven by an increase in cash and cash equivalents[202]. - The company’s total stockholders' equity decreased to $13,734,000 in 2025 from $63,340,000 in 2024, reflecting a significant decline due to the net loss and goodwill impairment[202]. Manufacturing and Operations - The company plans to consolidate its manufacturing operations to improve efficiency and support long-term growth, with a focus on specific centers of excellence[15][33]. - The company expects to close its manufacturing facility in Holliston, MA, transitioning production to its hub in Minneapolis, aligning operations with strategic logistical locations[112]. Compliance and Regulatory Risks - The company faces risks related to government regulations that could reduce demand for its products and adversely impact revenues[55]. - The company is subject to export control regulations that may restrict its ability to transact with certain foreign countries, potentially impacting international sales[61]. - The company received a notification from Nasdaq on April 4, 2025, indicating non-compliance with the minimum bid price requirement of $1.00 per share, based on a closing bid price for 30 consecutive business days[90]. Intellectual Property and Competition - The company has 11 issued patents worldwide as of December 31, 2025, with expiration dates ranging from 2028 to 2044[39]. - The life sciences industry is highly competitive, with many competitors having greater resources, which may impact the company's market position[49]. - The company faces risks related to intellectual property litigation, which could result in reduced revenue if unable to obtain necessary licenses[88][89]. Employee and Labor Market - As of December 31, 2025, the company employed 339 employees, including 316 full-time employees, with the majority located in the United States (192 full-time) and Germany (51 full-time)[45]. - The company operates in competitive labor markets, particularly in Boston, Minneapolis, England, and Germany, which may impact its ability to hire and retain qualified personnel[87]. Currency and Economic Factors - Changes in foreign currency exchange rates had a favorable effect on revenues of $1.2 million and an unfavorable effect on expenses of $1.5 million during the year ended December 31, 2025[151]. - Levels of inflation and interest rates could negatively impact revenues, profitability, and borrowing costs, potentially leading to reduced profit margins and adverse effects on financial results and net income[63]. Internal Controls and Financial Reporting - Material weaknesses in internal controls over financial reporting were identified as of December 31, 2024, but have been remediated by December 31, 2025[70][71]. - The company completed remediation of previously disclosed material weaknesses in internal controls over financial reporting as of December 31, 2025[177]. - The company has not made any changes to its internal control over financial reporting that materially affected its effectiveness during the year ended December 31, 2025[178].